Loading organizations...
§ Private Profile · Cincinnati, OH, USA
A pharmaceutical company developing deudomperidone (CIN-102) for chronic gastroparesis, addressing an unmet need for therapy.
Based in Cincinnati, Ohio, CinDome Pharma is a clinical-stage biotechnology company that develops deudomperidone (CIN-102), an engineered formulation of domperidone designed to treat chronic gastroparesis. The organization operates as a dedicated portfolio company of CinRx Pharma, advancing this specific gastrointestinal drug through clinical development to address unmet medical needs for long-term therapy. CinDome Pharma recently secured a $40 million Series B funding extension to support its ongoing clinical trials and regulatory progression. This capital injection builds upon the broader financial backing of its parent entity, which has raised $103 million across its portfolio from prominent institutional investors including Perceptive Advisors. The company's clinical focus has gained additional market relevance amid the rising prevalence of gastroparesis associated with GLP-1 drug side effects, a trend noted by executives like James O'Mara. CinDome Pharma was founded in 2016 by Jon Isaacsohn.
CinDome Pharma has raised $40.0M across 1 funding round.
CinDome Pharma has raised $40.0M in total across 1 funding round.
CinDome Pharma has raised $40.0M in total across 1 funding round.
CinDome Pharma's investors include Jonathan Isaacsohn, Perceptive Advisors.
CinDome Pharma has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series B Extension in May 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 16, 2024 | $40M Series B Plus | — | Jonathan Isaacsohn, Perceptive Advisors | Announced |